Last Updated: November 8, 2026

Details for Patent: 12,290,596

Name: Drug Patent Intelligence for US Patent 12290596
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 12,290,596 protect, and when does it expire?

Patent 12,290,596 protects OPVEE and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 12,290,596

Title:	Compositions and methods for the treatment of opioid overdose
Abstract:	Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Inventor(s):	Phil Skolnick, Mark Ellison, Roger Crystal
Assignee:	Indivior Inc , Indivior UK Ltd
Application Number:	US17/881,306
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,290,596
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,290,596

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior	OPVEE	nalmefene hydrochloride	SPRAY;NASAL	217470-001	May 22, 2023		RX	Yes	Yes	12,290,596	⤷ Start Trial				EMERGENCY TREATMENT OF A KNOWN OR SUSPECTED OPIOID OVERDOSE/SYMPTOM THEREOF IN A HUMAN CAUSED BY NATURAL OR SYNTHETIC OPIOIDS, SUCH AS REMIFENTANIL-INDUCED RESPIRATORY DEPRESSION, WITH 2.7MG NALMEFENE, ADMINISTERED AS 3MG NALMEFENE HYDROCHLORIDE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 12,290,596

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022323269	⤷ Start Trial
Canada	3227828	⤷ Start Trial
European Patent Office	4380570	⤷ Start Trial
Israel	310566	⤷ Start Trial
Mexico	2024001659	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.